CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial

CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial

Abstract Approximately 78.3% of patients with t(8;21) acute myeloid leukemia (AML) express CD19, making it a potential target for chimeric antigen receptor (CAR)-T cell therapy focused on CD19. This prospective phase II trial (NCT03896854) evaluated the safety and efficacy of CD19 CAR-T cell treatme...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia Yin, Qing-Ya Cui, Hai-Ping Dai, Chang-Ju Qu, Zheng Li, Li-Qing Kang, Wei Cui, Xiao-Peng Tian, Xia-Ming Zhu, Lei Yu, De-Pei Wu, Xiao-Wen Tang
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Journal of Hematology & Oncology
Subjects:
Chimeric antigen receptor T cells
CAR-T CD19
t(8;21) translocation
Acute myeloid leukemia
Relapsed
Online Access:https://doi.org/10.1186/s13045-025-01708-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13045-025-01708-z

Similar Items